BCL2 and fibrosarcoma: As compared to WT controls, intravenously injected Bcl2-/- de-iniDCs were more efficient in controlling the growth of orthotopic TC1 NSCLC (Fig. 4A-D) and MCA205 fibrosarcomas (Fig. S8C-F), indicating that BCL2 inhibition in DCs alone is sufficient to improve immunosurveillance.